FGEN - FibroGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

FibroGen, Inc.

409 Illinois Street
San Francisco, CA 94158
United States
415-978-1200
http://www.fibrogen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees461

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas B. NeffFounder, Chairman & CEO1.75M20.39M1954
Mr. Pat CotroneoSr. VP of Fin. & CFO782.94k6.35M1964
Dr. K. Peony YuChief Medical Officer954.55k1.12M1962
Dr. Barry A. BerkowitzFounderN/AN/AN/A
Dr. Michael J. MartinelliSr. VP of Technical Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Corporate Governance

FibroGen, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.